Black tea consumption dose-dependently improves flow-mediated dilation in healthy males
- PMID: 19516176
- DOI: 10.1097/HJH.0b013e328326066c
Black tea consumption dose-dependently improves flow-mediated dilation in healthy males
Abstract
Objectives: Flavonoids may protect against cardiovascular disease. Tea is a major source of dietary flavonoids. Studies indicate black tea improves endothelial function but data on arterial haemodynamics, blood pressure (BP) and insulin resistance are equivocal. Inconsistency may be due to flaws in study design or flavonoid doses tested. Further, no study has evaluated the dose-response curve. Our study aimed to test the effects of various doses of black tea on vascular function, BP and insulin resistance.
Methods: According to a randomized, double-blind, controlled, cross-over design, 19 healthy men were assigned to receive either five treatments with a twice daily intake of black tea (0, 100, 200, 400 and 800 mg tea flavonoids/day) in five periods lasting 1 week each.
Results: Black tea dose dependently increased flow-mediated dilation (FMD) from 7.8% (control) to 9.0, 9.1, 9.6 and 10.3% after the different flavonoid doses, respectively (P = 0.0001). Already 100 mg/day (less than 1 cup of tea) increased FMD compared with control (P = 0.0113). FMD improvement after 800 mg/day was significant compared with control (P < 0.0001) but also to 100 mg/day (P = 0.0121) and 200 mg/day (P = 0.0275). Black tea intake decreased office systolic (-2.6 mmHg, P = 0.0007) and diastolic (-2.2 mmHg, P = 0.006) BP as well as stiffness index (P = 0.0159) without changes in other parameters studied.
Conclusion: Our study is the first showing black tea ingestion dose dependently improved FMD and decreased peripheral arterial stiffness in healthy volunteers. Our data suggest that worldwide all tea drinkers could benefit from protective cardiovascular effects exerted by tea.
Similar articles
-
Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals.J Hypertens. 2015 Feb;33(2):294-303. doi: 10.1097/HJH.0000000000000412. J Hypertens. 2015. PMID: 25380152 Clinical Trial.
-
Tea flavonoids and cardiovascular disease.Asia Pac J Clin Nutr. 2008;17 Suppl 1:288-90. Asia Pac J Clin Nutr. 2008. PMID: 18296358 Review.
-
The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea.Br J Nutr. 2008 Apr;99(4):863-8. doi: 10.1017/S0007114507838992. Epub 2007 Oct 5. Br J Nutr. 2008. PMID: 17916273
-
Addition of milk prevents vascular protective effects of tea.Eur Heart J. 2007 Jan;28(2):219-23. doi: 10.1093/eurheartj/ehl442. Epub 2007 Jan 9. Eur Heart J. 2007. PMID: 17213230
-
Effects of tea and tea flavonoids on endothelial function and blood pressure: a brief review.Clin Exp Pharmacol Physiol. 2006 Sep;33(9):838-41. doi: 10.1111/j.1440-1681.2006.04450.x. Clin Exp Pharmacol Physiol. 2006. PMID: 16922817 Review.
Cited by
-
Effects of Zofenopril on Arterial Stiffness in Hypertension Patients.Mol Biotechnol. 2023 Sep 13. doi: 10.1007/s12033-023-00861-5. Online ahead of print. Mol Biotechnol. 2023. PMID: 37702881
-
Acute and Long Term Effects of a Nutraceutical Combination on Lipid Profile, Glucose Metabolism and Vascular Function in Patients with Dyslipidaemia with and Without Cigarette Smoking.High Blood Press Cardiovasc Prev. 2021 Sep;28(5):483-491. doi: 10.1007/s40292-021-00468-4. Epub 2021 Sep 13. High Blood Press Cardiovasc Prev. 2021. PMID: 34519016 Free PMC article.
-
Theaflavins decrease skeletal muscle wasting in disuse atrophy induced by hindlimb suspension in mice.J Clin Biochem Nutr. 2021 May;68(3):228-234. doi: 10.3164/jcbn.20-68. Epub 2020 Nov 14. J Clin Biochem Nutr. 2021. PMID: 34025025 Free PMC article.
-
Impact of green tea on the deleterious cardiometabolic effects of 7-days unhealthy lifestyle in young healthy males.Physiol Rep. 2021 Mar;9(5):e14720. doi: 10.14814/phy2.14720. Physiol Rep. 2021. PMID: 33682367 Free PMC article.
-
Black tea and maintenance of normal endothelium-dependent vasodilation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.EFSA J. 2018 Jan 16;16(1):e05138. doi: 10.2903/j.efsa.2018.5138. eCollection 2018 Jan. EFSA J. 2018. PMID: 32625684 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources